Enliven to sell $200M in stock after positive drug trial
Enliven Therapeutics recently reported positive data from a clinical trial for one of its drug candidates, and plans to raise $200 million in a public stock offering.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
BOULDER — Biodesix Inc. (Nasdaq: BDSX), a life-sciences company that specializes in developing tools to…
-
Colorado life-sciences companies raised $2.15 billion from investors in 2024, according to a report from…
-
BOULDER — PanTheryx Inc., a Boulder-based life-sciences company that makes health products from bovine colostrum,…
-
NewVale Capital LLC recently closed its oversubscribed inaugural fund with $167 million to deploy in…
